NU 641 ADVANCED PHARMACOLOGY
MIDTERM EXAM QUESTIONS AND
ANSWERS AND EXPLANATIONS |
LATEST - REGIS
1. A patient is prescribed a drug that is a known inhibitor of the CYP3A4 enzyme system.
What is the most likely consequence if they take another drug metabolized by the same
system?
A. Decreased plasma levels of the second drug
B. Increased risk of toxicity of the second drug
C. Rapid excretion of the second drug
D. Decreased therapeutic effect of the second drug
Answer: B
Conceptual Explanation: CYP450 inhibitors block the metabolism of substrate drugs,
leading to increased plasma concentrations and a higher risk of toxicity.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. Metabolism of a drug in the liver before it reaches systemic circulation
B. The binding of drugs to plasma proteins in the blood
C. The rapid excretion of drugs via the kidneys
,D. The initial distribution of a drug to highly perfused organs
Answer: A
Conceptual Explanation: The first-pass effect refers to the metabolic reduction of a drug’s
concentration by the liver after oral administration and before it enters the systemic
circulation.
3. A patient with heart failure is started on an ACE inhibitor. Which electrolyte abnormality
must the provider monitor for most closely?
A. Hyperkalemia
B. Hyponatremia
C. Hypokalemia
D. Hypocalcemia
Answer: A
Conceptual Explanation: ACE inhibitors block aldosterone secretion, which can lead to
potassium retention, resulting in hyperkalemia.
4. Which pharmacological parameter determines the dosing interval of a medication?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Therapeutic index
, Answer: C
Conceptual Explanation: The half-life (t1/2) is the time required for the concentration of
the drug in the body to decrease by 50% and is the primary factor in determining dosing
frequency.
5. In a patient with chronic kidney disease, what adjustment is usually required for drugs
primarily excreted by the kidneys?
A. Decrease the dose or increase the dosing interval
B. Decrease the dosing interval
C. Increase the dose
D. Switch to a drug with a shorter half-life
Answer: A
Conceptual Explanation: Reduced renal clearance requires dosage reduction or longer
intervals between doses to prevent accumulation and toxicity.
6. A patient taking Warfarin (Coumadin) is prescribed Amiodarone. What is the expected
interaction?
A. Decreased INR due to enzyme induction
B. Rapid metabolism of Amiodarone
C. No change in INR
D. Increased INR due to enzyme inhibition
MIDTERM EXAM QUESTIONS AND
ANSWERS AND EXPLANATIONS |
LATEST - REGIS
1. A patient is prescribed a drug that is a known inhibitor of the CYP3A4 enzyme system.
What is the most likely consequence if they take another drug metabolized by the same
system?
A. Decreased plasma levels of the second drug
B. Increased risk of toxicity of the second drug
C. Rapid excretion of the second drug
D. Decreased therapeutic effect of the second drug
Answer: B
Conceptual Explanation: CYP450 inhibitors block the metabolism of substrate drugs,
leading to increased plasma concentrations and a higher risk of toxicity.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. Metabolism of a drug in the liver before it reaches systemic circulation
B. The binding of drugs to plasma proteins in the blood
C. The rapid excretion of drugs via the kidneys
,D. The initial distribution of a drug to highly perfused organs
Answer: A
Conceptual Explanation: The first-pass effect refers to the metabolic reduction of a drug’s
concentration by the liver after oral administration and before it enters the systemic
circulation.
3. A patient with heart failure is started on an ACE inhibitor. Which electrolyte abnormality
must the provider monitor for most closely?
A. Hyperkalemia
B. Hyponatremia
C. Hypokalemia
D. Hypocalcemia
Answer: A
Conceptual Explanation: ACE inhibitors block aldosterone secretion, which can lead to
potassium retention, resulting in hyperkalemia.
4. Which pharmacological parameter determines the dosing interval of a medication?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Therapeutic index
, Answer: C
Conceptual Explanation: The half-life (t1/2) is the time required for the concentration of
the drug in the body to decrease by 50% and is the primary factor in determining dosing
frequency.
5. In a patient with chronic kidney disease, what adjustment is usually required for drugs
primarily excreted by the kidneys?
A. Decrease the dose or increase the dosing interval
B. Decrease the dosing interval
C. Increase the dose
D. Switch to a drug with a shorter half-life
Answer: A
Conceptual Explanation: Reduced renal clearance requires dosage reduction or longer
intervals between doses to prevent accumulation and toxicity.
6. A patient taking Warfarin (Coumadin) is prescribed Amiodarone. What is the expected
interaction?
A. Decreased INR due to enzyme induction
B. Rapid metabolism of Amiodarone
C. No change in INR
D. Increased INR due to enzyme inhibition
